Severe or Greater Tricuspid RegurgitationNCT07433504
A Prospective, Multicenter, Randomized Controlled Clinical Trial of Transcatheter Tricuspid Valve Clipping Systems.
A study testing Experimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT and Guideline Directed Medical Therapy in people with Severe or Greater Tricuspid Regurgitation, run by Shanghai Huihe Medical Technology Co., Ltd at 1 site in China.
Trial summary
The transcatheter tricuspid valve clipping system is specially designed for the treatment of tricuspid regurgitation. Under the guidance of ultrasound and DSA imaging, the investigational device is advanced into the right ventricle via a femoral or jugular venous puncture approach. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Severe or Greater Tricuspid Regurgitation
- What is being tested?
- Experimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT and Guideline Directed Medical Therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 132 participants
- Where
- 1 siteChina
- Study dates
- 28 Jan 2026to 31 Dec 2031
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years, male or female;
- Patients with severe or greater tricuspid regurgitation (TR ≥ 4+) judged by the local study team to have received adequate treatment according to applicable standards and remained stable for at least 30 days (TR grading to be determined by the core laboratory);
- Adequate treatment is defined as:
- Oral diuretic therapy for tricuspid regurgitation at a stable dose for at least 30 days; Guideline-directed medical therapy for heart failure (if applicable) according to heart failure subtype with different ejection fractions, at a stable dose for at least 30 days; For subjects with mitral regurgitation (MR ≥ 3+), atrial fibrillation, or coronary artery disease: medical therapy for ≥ 30 days, or ≥ 30 days post device-based therapy with stable clinical status.
- Stable dose is defined as: dose increase ≤ 100% or dose reduction ≤ 50%.
- The multidisciplinary heart team (comprising cardiologists, cardiovascular surgeons, imaging specialists, anesthesiologists, etc., with at least 2 physicians) judges that the subject is at moderate or high surgical risk (Tri-Score ≥ 4.0) and is expected to benefit from tricuspid edge-to-edge repair;
Show all 11Show fewer
- Left ventricular ejection fraction (LVEF) ≥ 20%;
- Presence of symptoms attributable to tricuspid regurgitation (e.g., chest distress, dyspnea, shortness of breath, lower extremity edema, ascites), or asymptomatic subjects with right ventricular dilation or impaired right ventricular function (as determined by the core laboratory);
- Impaired right ventricular function is defined as: tricuspid annular plane systolic excursion (TAPSE) < 17 mm or fractional area change (FAC) < 35%.
- NYHA functional class II to IV, inclusive;
- Subject voluntarily agrees to participate in the clinical trial and provides written informed consent, or consent is provided by the subject's legal representative.
Who cannot join
- Patients with pulmonary artery systolic pressure ≥ 60 mmHg: if right heart catheterization was performed, results shall be based on right heart catheterization; if not performed, results shall be based on echocardiography (assessed by the core laboratory).
- Tricuspid valve anatomy that, in the judgment of the core laboratory, may preclude implantation, proper positioning of the tricuspid clip device, fail to sufficiently reduce TR severity, or achieve adequate leaflet apposition, including but not limited to:
- Severe calcification in the leaflet grasping zone; Severe leaflet perforation, cleft, or other lesions that impede device implantation; Ebstein's anomaly; TR expected to be unamenable to reduction to grade 2+ or lower post-procedure with edge-to-edge repair.
- Presence of a prosthetic valve or annuloplasty ring at the tricuspid valve position, or prior tricuspid valve surgery that, in the judgment of the core laboratory, would interfere with study device implantation or therapeutic effect.
- Tricuspid stenosis, defined as tricuspid valve area ≤ 1.0 cm² and/or mean tricuspid gradient > 5 mmHg (assessed by the core laboratory).
- Tricuspid valve anatomy that cannot be evaluated by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE).
Show all 30Show fewer
- Evidence of mass, thrombus, or vegetation in the cardiac chambers, access-related veins (jugular or femoral vein, depending on the selected access route for the individual subject), superior vena cava, or inferior vena cava (depending on the selected access route for the individual subject).
- Patients in whom bilateral femoral veins are unsuitable for 23 Fr sheath access due to disease or anatomy, and bilateral jugular veins are unsuitable for 21 Fr sheath access (i.e., both transfemoral and transjugular access are contraindicated).
- Severe uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg).
- Prior implantation of a pacemaker (excluding leadless pacemakers) or implantable cardioverter-defibrillator (ICD), or planned implantation of a pacemaker (excluding leadless pacemakers) or ICD that, in the judgment of the core laboratory, would interfere with study device implantation or therapeutic effect, or where study device implantation would interfere with the pacemaker or ICD.
- Hemodynamic instability, defined as systolic blood pressure < 90 mmHg, cardiogenic shock, requirement for inotropic support, intra-aortic balloon pump, or other hemodynamic support devices.
- End-stage refractory heart failure requiring specialized interventions (e.g., mechanical circulatory support, heart transplantation, etc.).
- Patients with more than moderate aortic stenosis, mitral stenosis, aortic regurgitation, or mitral regurgitation; or patients scheduled for cardiac surgery within the next 12 months.
- Percutaneous coronary intervention within the previous 1 month.
- Myocardial infarction within the previous 1 month or known unstable angina.
- Cerebrovascular accident within the previous 3 months.
- Patients with active infective endocarditis or active rheumatic heart disease.
- Patients with coagulopathy, hypercoagulable state, or anemia (hemoglobin < 90 g/L).
- Patients with acute infection or other severe infection.
- Patients with active peptic ulcer or active gastrointestinal bleeding.
- Transient ischemic attack (TIA) within 30 days, or prior stroke with permanent disability (mRS > 4).
- Severe end-stage disease (e.g., malignant tumor, severe pulmonary disease, hepatic disease, renal failure) with life expectancy < 1 year.
- Patients with known hypersensitivity or contraindications to the study device materials or study medications (e.g., antiplatelet agents, anticoagulants).
- Alcohol, drug, or substance addiction.
- Patients with cognitive impairment.
- History of primary or persistent epilepsy poorly controlled by medication, or psychiatric disorders.
- Participation in any other clinical trial (except registry studies) within 30 days prior to signing the informed consent form.
- Chronic dialysis patients.
- Females who are pregnant, breastfeeding, or planning to become pregnant during the clinical trial.
- Any other conditions deemed inappropriate by the investigator for participation in this clinical trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Junbo Ge contact
China1 site, 1 recruiting
- Recruiting
Zhongshan Hospital, Fudan University
Shanghai
About this study
Official title: A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Transcatheter Tricuspid Valve Clipping Systems in Patients With Severe or Greater Tricuspid Regurgitation.
The transcatheter tricuspid valve clipping system is specially designed for the treatment of tricuspid regurgitation. Under the guidance of ultrasound and DSA imaging, the investigational device is advanced into the right ventricle via a femoral or jugular venous puncture approach. The clipping component grasps the edges of the dysfunctional valve leaflets (usually unable to close properly), thereby reducing the area of the tricuspid orifice that fails to coapt normally, achieving minimally invasive treatment of tricuspid regurgitation.
- Being tested
- Experimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT, Guideline Directed Medical Therapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMTDevice
This is a prospective, multi-center, randomized controlled clinical trial. Eligible patients with severe or greater tricuspid regurgitation will be enrolled in accordance with the inclusion and exclusion criteria specified in the study protocol. A total of 132 patients who meet all inclusion criteria and none of the exclusion criteria during pre-treatment screening will be randomized in a 2:1 ratio to either the experimental group or the control group.
Guideline Directed Medical TherapyDrug
Guideline Directed Medical Therapy
| Study group | Role | What they receive |
|---|---|---|
| Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT | Experimental | Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT Receives: Device: Experimental: Transcatheter tricuspid valve repair using the transcatheter tricuspid valve clipping system +GDMT |
| Guideline Directed Medical Therapy | Active comparator | GDMT Receives: Drug: Guideline Directed Medical Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of subjects free of all-cause death or tricuspid valve reoperation, free of heart failure readmission, and with ≥15-point improvement in the Kansas City Cardiomyopathy Questionnaire score at 1 year after treatment.
Measured: at 1 year after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start28 Jan 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Severe or Greater Tricuspid RegurgitationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 132 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Huihe Medical Technology Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07433504
- Sponsor's protocol ID
- CSP-TC-02
- Status last verified
- Feb 2026
- First submitted
- 20 Feb 2026
- Last updated
- 25 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No